The overall incidence of TBI in Europe is estimated between 198 and 325 people per 100,000 per year, with fatal outcome in 10.5 people per 100,000 per year. Direct and indirect lifetime economic costs of mild, moderate and severe TBI are estimated at 90 billion dollars in the USA. Thus TBI represents an important medical condition with a significant impact on personal and public health.

At the moment there is no specific treatment for TBI. Treatment options depend on the severity of the TBI and its symptoms.

A potential treatment strategy includes the use of “neurorecovery” drugs. New clinical trials with the multidimensional analysis approach are setting a new gold standard. In the future, we expect some positive results which will help us to better treat TBI patients. Stay tuned!

Please find more information about this new treatment option in the report of the EVER symposium during EAN.